Jacobs Levy Equity Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Jacobs Levy Equity Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-245,018	Closed	-$1.3M	–	1147
2021 Q2	$1.3M	Buy	245,018 +130,579	+114%	+$628K	0.01%	693
2021 Q1	$532K	Hold	114,439	–	–	﹤0.01%	858
2020 Q4	$378K	Buy	+114,439	New	+$435K	﹤0.01%	887
2018 Q2	–	Sell	-12,400	Closed	-$108K	–	1124
2018 Q1	$108K	Buy	+12,400	New	+$134K	﹤0.01%	967

Other funds holding ZYNE

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Jacobs Levy Equity Management's ZYNE Position: Q3 2021 in Review

Jacobs Levy Equity Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2021, closing a stake of 245,018 shares — an estimated $1.3M sold.

Jacobs Levy Equity Management first reported a position in ZYNE in Q1 2018 and held it in 4 quarters. The position peaked at $1.3M in Q2 2021. 58 funds tracked by Wall St. Rank hold ZYNE as of Q3 2021.

Jacobs Levy Equity Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2021 after selling out during the quarter.
Jacobs Levy Equity Management sold 245,018 Zynerba Pharmaceuticals, Inc shares in Q3 2021, an estimated $1.3M.
Jacobs Levy Equity Management first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2018 and held it in 4 quarters.
Jacobs Levy Equity Management's Zynerba Pharmaceuticals, Inc position peaked at $1.3M in Q2 2021.
58 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2021, filed 15 Nov 2021.